Oxford BioMedica Share Price (OXB)

3.69 +0.17 (+4.83%) delayed: 1:29PM BST
Bid price 3.65 Open price 3.76
Ask price 3.72 Prev close 3.52
High price 3.76 Spread 1.88%
Low price 3.53 Volume 3,065,175

Register now for FREE live Oxford BioMedica share prices, Oxford BioMedica stock quotes, charts, trades market news and much much more. Why not upgrade to a premium service and get Oxford BioMedica Level 2 Data, indepth research tools and investor commentary for Oxford BioMedica (OXB) and other London Stock Exchange equities.

Oxford BioMedica Share Price Chart

Advanced Charts >>

Register now for FREE Oxford BioMedica share price charts

Oxford BioMedica Share Price Information

Name Oxford BioMedica Epic OXB
Sector Pharmaceuticals & Biotechnology ISIN GB0006648157
Activites Oxford BioMedica plc is a biopharmaceutical company developing innovative gene-based medicines and therapeutic vaccines that aim to improve the lives of patients with high unmet medical needs. The Company's technology platform includes a highly efficient LentiVector gene delivery system, which has specific advantages for targeting diseases of the central nervous system and the eye; and a unique tumour antigen (5T4), which is an ideal target for anti-cancer therapy. Through in-house and collaborative research, Oxford BioMedica has a broad pipeline with current partners and licensees including Sanofi, Pfizer, Novartis, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen Idec, Emergent BioSolutions, ImaginAb and Immune Design Corp. Index n/a

Oxford BioMedica Key Numbers

Latest Share Price (p) 3.69 Net Gearing (%) 60.95
Market Capitalisation (£m) 114.56 Gross Gearing (%) 78.99
Shares in issue (m) 3,087.95 Debt Ratio 71.84
P/E Ratio -7.28 Debt-to-Equity Ratio 0.68
Total dividends per share (p) 0.00 Assets / Equity Ratio 4.76
Dividend Yield (%) 0.00 Price to book value 10.52
Dividend cover (x) 0.00 ROCE (%) -43.90
Earning per share (p) -0.51 EPS Growth (%) -18.60
52 week high / low 8.45 / 2.57 DPS Growth (%) n/a

Oxford BioMedica Director Deals

Dec.Date Type Director Pos No. of Shares
25/10/2016 BUY Dr Lorenzo Tallarigo CH 77,864
26/09/2016 LOF Dr Lorenzo Tallarigo CH 79,988
25/08/2016 BUY Dr Lorenzo Tallarigo CH 62,257
25/07/2016 LOF Dr Lorenzo Tallarigo CH 63,351
27/06/2016 BUY Dr Lorenzo Tallarigo CH 62,847

More Oxford BioMedica Director Deals >>

Oxford BioMedica Company News

17:30 25/10/2016

Director Deals - Oxford BioMedica PLC (OXB)

Dr Lorenzo Tallarigo, Chairman, bought 77,864 shares in the company on the 25th October 2016 at a price of 3.40p. The Director now holds 512,699 shares. Story provided by StockMarketWire.com Director deals data provided by www.directorsholdings.com

16:40 25/10/2016

Director/PDMR Shareholding

RNS Number : 4351N Oxford Biomedica PLC 25 October 2016               Director Dealings / Market Share Purchase   Oxford, UK - 25 October 2016:   Oxford BioMedica plc ("Oxford BioMedica" or "the Group") (LSE: OXB), a leading gene and cell...

11:40 21/10/2016

Broker Forecast - Jefferies International issues a broker note on Oxford BioMedica PLC

Jefferies International today initiates coverage of Oxford BioMedica PLC (LON:OXB) with a buy investment rating and price target of 8p. Story provided by StockMarketWire.com

More Oxford BioMedica Company News >>

Register now for FREE Oxford BioMedica company news

Oxford BioMedica Share Price Discussions

8 months ago

CANCER drug co. Oxford Biomedica charts (OXB)

OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles. So here is a new title This one has got the charts at the top again & has a link to the old one. http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

more than 1 year ago


Very strong rumours of a further predator around. CAT,WYEYH,JOHNSON&JOHNSON,MERCK to name a few.............could be an exciting week ...!

more than 1 year ago


Very strong rumours of a further predator.........CAT,JOHNSON&JOHNSON,WYETH,MERCK to name a few. Could be an interesting week..!

Register now for FREE Oxford BioMedica share price discussions